Gemphire Therapeutics Inc. (NASDAQ:GEMP) has earned a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $24.60.

GEMP has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Thursday, November 16th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective (up from $21.00) on shares of Gemphire Therapeutics in a report on Tuesday, November 14th. Canaccord Genuity set a $31.00 price objective on shares of Gemphire Therapeutics and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Roth Capital initiated coverage on shares of Gemphire Therapeutics in a report on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective on the stock.

Gemphire Therapeutics (NASDAQ GEMP) traded down $0.09 during midday trading on Friday, reaching $7.77. 32,900 shares of the company’s stock traded hands, compared to its average volume of 64,932. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.17 and a current ratio of 4.17. Gemphire Therapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $21.59.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.14). sell-side analysts anticipate that Gemphire Therapeutics will post -3.31 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bamco Inc. NY purchased a new stake in shares of Gemphire Therapeutics during the third quarter valued at $2,709,000. Cambridge Investment Research Advisors Inc. lifted its position in Gemphire Therapeutics by 4.5% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock valued at $1,520,000 after purchasing an additional 6,900 shares during the period. Comerica Bank acquired a new position in Gemphire Therapeutics during the third quarter valued at $850,000. Northpointe Capital LLC lifted its position in Gemphire Therapeutics by 91.8% during the third quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock valued at $4,943,000 after purchasing an additional 249,077 shares during the period. Finally, Advisory Services Network LLC acquired a new position in Gemphire Therapeutics during the second quarter valued at $139,000. 32.11% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/08/gemphire-therapeutics-inc-gemp-given-consensus-recommendation-of-buy-by-analysts.html.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.